A Phase 1, Open-Label Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs BIIB 080 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Biogen
- 10 Jan 2025 Planned End Date changed from 28 Jul 2025 to 30 Jul 2026.
- 10 Jan 2025 Planned primary completion date changed from 20 Feb 2025 to 16 Feb 2026.
- 10 Jan 2025 Planned initiation date changed from 31 Jan 2025 to 20 Mar 2025.